Variation in revascularisation use and outcomes of patients in hospital with acute myocardial infarction across six high income countries: cross sectional cohort study.
Adult
Cohort Studies
Cross-Sectional Studies
Developed Countries
Hospital Mortality
Hospitals
Humans
Myocardial Infarction
/ epidemiology
Non-ST Elevated Myocardial Infarction
/ diagnosis
Ontario
Percutaneous Coronary Intervention
Retrospective Studies
Risk Factors
ST Elevation Myocardial Infarction
/ therapy
Treatment Outcome
United States
/ epidemiology
Journal
BMJ (Clinical research ed.)
ISSN: 1756-1833
Titre abrégé: BMJ
Pays: England
ID NLM: 8900488
Informations de publication
Date de publication:
04 05 2022
04 05 2022
Historique:
entrez:
4
5
2022
pubmed:
5
5
2022
medline:
7
5
2022
Statut:
epublish
Résumé
To compare treatment and outcomes for patients admitted to hospital with a primary diagnosis of ST elevation or non-ST elevation myocardial infarction (STEMI or NSTEMI) in six high income countries with very different healthcare delivery systems. Retrospective cross sectional cohort study. Patient level administrative data from the United States, Canada (Ontario and Manitoba), England, the Netherlands, Israel, and Taiwan. Adults aged 66 years and older admitted to hospital with STEMI or NSTEMI between 1 January 2011 and 31 December 2017. The three categories of outcomes were coronary revascularisation (percutaneous coronary intervention or coronary artery bypass graft surgery), mortality, and efficiency (hospital length of stay and 30 day readmission). Rates were standardised to the age and sex distribution of the US acute myocardial infarction population in 2017. Outcomes were assessed separately for STEMI and NSTEMI. Performance was evaluated longitudinally (over time) and cross sectionally (between countries). The total number of hospital admissions ranged from 19 043 in Israel to 1 064 099 in the US. Large differences were found between countries for all outcomes. For example, the proportion of patients admitted to hospital with STEMI who received percutaneous coronary intervention in hospital during 2017 ranged from 36.9% (England) to 78.6% (Canada; 71.8% in the US); use of percutaneous coronary intervention for STEMI increased in all countries between 2011 and 2017, with particularly large rises in Israel (48.4-65.9%) and Taiwan (49.4-70.2%). The proportion of patients with NSTEMI who underwent coronary artery bypass graft surgery within 90 days of admission during 2017 was lowest in the Netherlands (3.5%) and highest in the US (11.7%). Death within one year of admission for STEMI in 2017 ranged from 18.9% (Netherlands) to 27.8% (US) and 32.3% (Taiwan). Mean hospital length of stay in 2017 for STEMI was lowest in the Netherlands and the US (5.0 and 5.1 days) and highest in Taiwan (8.5 days); 30 day readmission for STEMI was lowest in Taiwan (11.7%) and the US (12.2%) and highest in England (23.1%). In an analysis of myocardial infarction in six high income countries, all countries had areas of high performance, but no country excelled in all three domains. Our findings suggest that countries could learn from each other by using international comparisons of patient level nationally representative data.
Identifiants
pubmed: 35508312
doi: 10.1136/bmj-2021-069164
pmc: PMC9066381
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e069164Subventions
Organisme : NIA NIH HHS
ID : R01 AG058878
Pays : United States
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/disclosure-of-interest/ and declare: support from the US National Institute on Aging, ICES, Ontario Ministry of Health and Long term Care, Canadian Institute for Health Information for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; and no other relationships or activities that could appear to have influenced the submitted work.
Références
Spine (Phila Pa 1976). 2019 Oct 1;44(19):1371-1380
pubmed: 31261267
Can J Cardiol. 2019 Feb;35(2):107-132
pubmed: 30760415
Health Econ. 2015 Dec;24 Suppl 2:38-52
pubmed: 26633867
Med Care. 2005 Nov;43(11):1130-9
pubmed: 16224307
CMAJ Open. 2015 Oct 02;3(4):E413-8
pubmed: 27570759
BMJ. 2009 Jun 24;338:b2557
pubmed: 19553264
JAMA Intern Med. 2021 Mar 1;181(3):339-344
pubmed: 33369633
Health Serv Res. 2021 Dec;56 Suppl 3:1383-1393
pubmed: 34378190
Int J Qual Health Care. 2005 Dec;17(6):487-96
pubmed: 16155049
Lancet. 2021 Jun 19;397(10292):2337-2360
pubmed: 34051883
BMJ. 2016 Feb 17;352:i935
pubmed: 26888540
Arch Intern Med. 2005 Nov 28;165(21):2486-92
pubmed: 16314545
NCHS Data Brief. 2012 Aug;(103):1-8
pubmed: 23101933
Inquiry. 2010 Summer;47(2):124-34
pubmed: 20812461
Med Care. 2003 Jul;41(7):813-22
pubmed: 12835605
Health Aff (Millwood). 2007 Sep-Oct;26(5):1481-9
pubmed: 17848460
Int J Health Care Finance Econ. 2009 Mar;9(1):1-24
pubmed: 18592374
Med Care Res Rev. 2013 Apr;70(2):185-205
pubmed: 23035057
Eur Heart J. 2018 Jan 7;39(2):119-177
pubmed: 28886621
Lancet. 2003 Jan 4;361(9351):13-20
pubmed: 12517460
Health Serv Res. 2021 Dec;56 Suppl 3:1317-1334
pubmed: 34350586
Eur Heart J. 2013 Jul;34(26):1972-81
pubmed: 23364755
JAMA Netw Open. 2021 Apr 1;4(4):e215477
pubmed: 33871618
Circulation. 2018 Nov 13;138(20):e618-e651
pubmed: 30571511
Circulation. 2007 Jan 16;115(2):196-203
pubmed: 17190861
Lancet. 2014 Apr 12;383(9925):1305-1312
pubmed: 24461715
Circulation. 2011 Dec 6;124(23):e652-735
pubmed: 22064599
BMC Health Serv Res. 2017 May 2;17(1):318
pubmed: 28464878
Healthy People 2000 Stat Notes. 1995 Mar;(6):1-10
pubmed: 11762384
Int J Cardiol. 2014 Aug 1;175(2):240-7
pubmed: 24882696
PLoS Med. 2015 Oct 06;12(10):e1001885
pubmed: 26440803
Eur Heart J. 2019 Jan 7;40(2):87-165
pubmed: 30165437
Circ Cardiovasc Qual Outcomes. 2020 Jan;13(1):e006037
pubmed: 31957474
BMJ. 2015 Aug 07;351:h3913
pubmed: 26254445
JAMA. 2018 Mar 13;319(10):986-987
pubmed: 29536082
JAMA. 2018 Mar 13;319(10):1024-1039
pubmed: 29536101
Health Serv Res. 2021 Dec;56 Suppl 3:1335-1346
pubmed: 34390254
J Am Heart Assoc. 2018 Jan 25;7(3):
pubmed: 29371200
Heart. 2016 Jan 5;102(4):313-319
pubmed: 26732182
J Health Soc Behav. 2010;51 Suppl:S15-27
pubmed: 20943580
Lancet. 2018 Jun 2;391(10136):2236-2271
pubmed: 29893224
JAMA Cardiol. 2019 May 1;4(5):444-453
pubmed: 30969316
Int J Surg. 2014 Dec;12(12):1500-24
pubmed: 25046751
J Am Coll Cardiol. 2016 Mar 15;67(10):1235-1250
pubmed: 26498666
J Am Coll Cardiol. 2009 Dec 15;54(25):2423-9
pubmed: 20082933
Circ Cardiovasc Qual Outcomes. 2021 Mar;14(3):e007228
pubmed: 33596664
Circ Cardiovasc Qual Outcomes. 2014 Jul;7(4):581-8
pubmed: 24895449
Health Aff (Millwood). 2003 May-Jun;22(3):61-76
pubmed: 12757273
BMJ Open. 2017 Nov 12;7(11):e019217
pubmed: 29133337
Circ Cardiovasc Qual Outcomes. 2019 Nov;12(11):e005455
pubmed: 31665896
Open Med. 2010;4(1):e13-21
pubmed: 21686287
BMJ Evid Based Med. 2021 Apr;26(2):39-42
pubmed: 31732498
Arthritis Rheumatol. 2018 Apr;70(4):547-554
pubmed: 29287312
Health Econ. 2015 Dec;24 Suppl 2:88-101
pubmed: 26633870
PLoS One. 2020 Feb 6;15(2):e0228425
pubmed: 32027676
J Chin Med Assoc. 2021 Dec 1;84(12):1084-1091
pubmed: 34561408
Am J Cardiol. 2022 Apr 15;169:10-17
pubmed: 35063273
Health Serv Res. 2021 Dec;56 Suppl 3:1347-1357
pubmed: 34378796